John T. Fornetti Dds Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 100 S Stephenson Ave, Iron Mountain, MI 49801 Phone: 906-774-0100 |
Occhietti Selden Dental Pc Dentist Medicare: Not Enrolled in Medicare Practice Location: 225 Kent Street, Iron Mountain, MI 49801 Phone: 906-774-3032 Fax: 906-774-4018 |
Ted J Fornetti Dds Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1115 South Hemlock, Suite 1, Iron Mountain, MI 49801 Phone: 906-774-4444 Fax: 906-774-6949 |
News Archive
Current screening strategies for Down syndrome, caused by fetal trisomy 21 (T21), and Edwards syndrome, caused by fetal trisomy 18 (T18), have false positive rates of 2 to 3%, and false negative rates of 5% or higher. Positive screening results must be confirmed by amniocentesis or chorionic villus sampling, which carry a fetal loss rate of approximately 1 in 300 procedures. Now an international, multicenter cohort study finds that a genetic test to screen for trisomy 21 or 18 from a maternal blood sample is almost 100% accurate.
Electromed, Inc., which is a leader in developing innovative airway clearance therapy products for use by patients with compromised pulmonary function, today announced pricing of its initial public offering of 1,700,000 shares of common stock at a price of $4.00 per share, before underwriting discounts and commissions.
States that have expanded Medicaid eligibility under the Affordable Care Act have seen an "early surge in demand" for hip and knee replacement surgery, reports a study in the September 2, 2020 issue of The Journal of Bone & Joint Surgery.
Titan Enterprises announces the availability of a new version of its Atrato Ultrasonic flowmeter designed to deliver precise flow measurement of fluid flows from -10 to +110 degrees centigrade.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
› Verified 7 days ago